BLING III compared continuous with intermittent infusion of beta-lactam antibiotics in critically ill adults with sepsis. More than 7,000 patients were included in the primary analysis, receiving piperacillin-tazobactam or meropenem through one of the two dosing strategies. The primary endpoint was 90-day mortality. Continuous infusion produced a numerically lower mortality rate, but the difference did not reach conventional statistical significance. Clinical cure, however, was higher with continuous infusion. Why does this matter? Critically ill patients often have rapidly changing pharmacokinetics, altered volume of distribution and augmented or impaired renal clearance. Continuous infusion can improve the proportion of time that antibiotic concentrations remain above the pathogen's minimum inhibitory concentration, making it pharmacologically attractive. For HCPs, the practical message is that continuous beta-lactam infusion is a reasonable strategy to consider in selected critically ill patients, but it should not be promoted as a universal mortality-reducing intervention. Dose optimisation still depends on renal function, pathogen susceptibility, infection source and therapeutic drug-monitoring capability where available. The study directly supports CritiCARE's themes of antibiotic stewardship, sepsis management and pharmacotherapy in critical illness, particularly the programme's attention to antibiotic dosing and resistant infections.